Cancer drug Avastin shows early promise as tumour imaging agent
This article was originally published in Clinica
Executive Summary
Avastin (bevacizumab), the blockbuster anticancer drug developed by Roche and Genentech, could have a new application – imaging tumours. Scientists have found that it is better than the gold standard, fluorodeoxyglucose (FDG) for visualising pancreatic, breast and lung cancers in mice.